These medicines work by mimicking the action of a naturally occurring hormone called GLP-1, which is released from the intestine in response to food intake
Schedule follow-up to monitor for post-operative side effects or complications Schedule early outpatient or virtual visit 3 to 7 days of restart to monitor for GI symptoms, hypoglycemia if used in combination with other glucose-lowering agents, wound concerns, or infection
July 30, 2024: Study Links Active Ingredient in Some GLP-1 Drugs to Vision Loss June 17, 2024: Mounjaro Lawsuit Advances with First Status Conference Under New Judge Karen Marston June 9, 2024: Judge Karen Spence Marston to Preside Over Mounjaro Lawsuit May 20, 2024: Judge Change in Mounjaro Lawsuit Following Judge Pratters Death May 2, 2024: Mounjaro Lawsuit Science Day Scheduled for June 14, 2024 April 25, 2024: Mounjaro Lawsuit Initiated with Plaintiffs First Statement of the Case April 20, 2024: Mounjaro Lawsuits Still in Early Stages Mounjaro Lawsuits Still in Early Stages To date, the lawsuits against the maker of Mounjaro are still in the early stages of litigation
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial
All services are overseen by Patricia Arledge, MD
These results are promising, but more research is also needed to find out why GLP-1s may reduce death from all causes in this group
